Activated RAS promotes dimerization of members of the RAF kinase family [1] [2] [3] . ATP-competitive RAF inhibitors activate ERK signalling [4] [5] [6] [7] by transactivating RAF dimers 4 . In melanomas with mutant BRAF(V600E), levels of RAS activation are low and these drugs bind to BRAF(V600E) monomers and inhibit their activity. This tumourspecific inhibition of ERK signalling results in a broad therapeutic index and RAF inhibitors have remarkable clinical activity in patients with melanomas that harbour mutant BRAF(V600E) 8 . However, resistance invariably develops. Here, we identify a new resistance mechanism. We find that a subset of cells resistant to vemurafenib (PLX4032, RG7204) express a 61-kDa variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons 4-8, a region that encompasses the RAS-binding domain. p61BRAF(V600E) shows enhanced dimerization in cells with low levels of RAS activation, as compared to full-length BRAF(V600E). In cells in which p61BRAF(V600E) is expressed endogenously or ectopically, ERK signalling is resistant to the RAF inhibitor. Moreover, a mutation that abolishes the dimerization of p61BRAF(V600E) restores its sensitivity to vemurafenib. Finally, we identified BRAF(V600E) splicing variants lacking the RAS-binding domain in the tumours of six of nineteen patients with acquired resistance to vemurafenib. These data support the model that inhibition of ERK signalling by RAF inhibitors is dependent on levels of RAS-GTP too low to support RAF dimerization and identify a novel mechanism of acquired resistance in patients: expression of splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
RAF inhibitors have remarkable clinical activity in mutant BRAF melanomas that is limited by acquisition of drug resistance 8 . To identify new mechanisms of resistance, we generated cell lines resistant to vemurafenib by exposing the BRAF-mutant (V600E) melanoma cell line SKMEL-239 to a high dose of drug (2 mM). At this concentration, vemurafenib effectively inhibited ERK signalling and induced cell cycle arrest and cell death ( Fig. 1a -c, Supplementary Fig. 2a and data not shown). Five independent vemurafenib-resistant cell populations were generated after approximately 2 months of continuous drug exposure ( Fig. 1a ). We chose this approach rather than one of gradual adaptation to increasing concentrations of drug because it more closely represents the clinical situation 8 .
Resistance of SKMEL-239 cells to vemurafenib was associated with decreased sensitivity of ERK signalling to the drug (Fig. 1b, c and Supplementary Fig. 2b ). Analysis revealed the presence of two distinct classes of resistant clones. In the first, exemplified by the C3 clone, the half-maximum inhibitory concentration (IC 50 ) for phosphorylated MEK (pMEK) inhibition was more than 100-fold higher than that of the parental cell line ( Fig. 1d, e ). Despite a similar degree of resistance to the anti-proliferative and pro-apoptotic effects of the drug, the second class of clones, exemplified by clone C5, demonstrated only a modest increase in pMEK IC 50 (4.5-fold higher than the parental cell line). All five resistant clones retained sensitivity to the MEK inhibitor PD0325901 (ref. 9), albeit at slightly higher doses ( Supplementary  Fig. 3a, b ).
Analysis of DNA and complementary DNA derived from the five resistant clones showed that all retained expression of BRAF(V600E) ( Supplementary Fig. 4a, b ). We did not detect mutation in BRAF at the gatekeeper site 10 , RAS mutation, upregulation of receptor tyrosine kinase activity or COT overexpression ( Supplementary Fig. 5a , b and data not shown). Analysis of BRAF protein expression showed that each of the resistant clones expressed a 90 kDa band that comigrated with the band observed in parental cells. In the C1, C3 and C4 clones, a new band was also identified, at an approximate molecular weight of 61 kDa (p61BRAF(V600E), Fig. 1c and Supplementary Fig. 2b ). No band of this size was detected in parental SKMEL-239 cells or in a panel of 22 other melanoma cell lines ( Supplementary Fig. 6 ).
PCR analysis of cDNA showed the expected single transcript of 2.3 kilobases, representing full-length BRAF, in parental cells and two transcripts of 2.3 kb and 1.7 kb in C3 cells. The 1.7-kb product was a BRAF transcript that contained the V600E mutation and an inframe deletion of exons 4-8 ( Fig. 2a and Supplementary Fig. 7 ). This 1.7-kb transcript is predicted to encode a protein of 554 amino acids (molecular mass 61 kDa), consistent with the lower BRAF band detected by immunoblotting. Exons 4-8 include domains critical for RAF activation, most notably, the RAS-binding domain (RBD) and the cysteinerich domain (CRD) 3 . Analogous deletions in wild-type BRAF and CRAF promote RAF dimerization and render RAS activity dispensable for this process 1, 4 . The 61-kDa BRAF variant identified in C3 was also detected in clones C1 and C4 by quantitative PCR, with a primer that anneals specifically to the exons 3/9 junction ( Supplementary Fig. 8 ). Inspection of the BRAF locus on chromosome 7q34 by array CGH data suggested no evidence of an intragenic somatic deletion within the BRAF gene. The 1.7-kb transcript was cloned into an expression vector and expressed in 293H cells, alone or together with full-length wildtype BRAF. ERK signalling was resistant to vemurafenib when p61BRAF(V600E) was ectopically expressed (Fig. 2b ). Expression of p61BRAF(V600E) in parental SKMEL-239 cells or in HT-29 (BRAF(V600E)) cells also resulted in failure of vemurafenib to inhibit ERK signalling effectively ( Supplementary Fig. 9a, b ). To test whether ERK signalling in C3 cells was dependent on p61BRAF(V600E), we designed short interfering RNAs (siRNAs) directed against either the 3/9 splice junction or a region within the exon 4-8 deletion to suppress selectively the expression of p61BRAF(V600E) or full-length BRAF, respectively. In parental cells, ERK signalling was inhibited by knockdown of full-length BRAF(V600E) ( Supplementary Fig. 10a ). In C3 cells, phosphorylation of MEK, cyclin D1 expression and cell growth were inhibited upon knockdown of p61BRAF(V600E) but not of fulllength wild-type BRAF, ARAF or CRAF ( Supplementary Fig. 10b , c). Moreover, in C3 cells in which the expression of full-length BRAF or CRAF was knocked down, ERK signalling remained resistant to vemurafenib ( Supplementary Fig. 10d ).
Vemurafenib inhibits the kinase activity of RAF immunoprecipitated from cells, but activates intracellular RAF in BRAF wild-type cells 4 . This indicates that the conditions required for transactivation in vivo are not recapitulated in the in vitro assay. We tested whether p61BRAF(V600E) is also sensitive to this inhibitor in vitro. Although the in vitro activity of p61BRAF(V600E) was slightly higher than fulllength BRAF(V600E), similar concentrations of vemurafenib caused their inhibition in vitro ( Supplementary Fig. 11 ). These data indicate that resistance of p61BRAF(V600E) to vemurafenib is not due to its inability to bind the inhibitor.
It has been shown that the amino terminus of RAF negatively regulates the carboxy-terminal catalytic domain 11 and that truncation of the N terminus results in constitutive dimerization of the protein in the absence of activated RAS 1 . To ask whether deletion of exons 4-8 promotes dimerization of p61BRAF(V600E), we co-expressed two constructs encoding the same protein (either p61BRAF(V600E) or full-length BRAF(V600E)) but with different tags (Flag or V5) and then immunoblotted for V5 after immunoprecipitating Flag. As shown in Fig. 2c , dimerization of p61BRAF(V600E) was significantly elevated compared to that of full-length BRAF(V600E). The R509 residue is within the BRAF dimerization interface. Mutation of this residue to a histidine significantly diminishes dimerization of wild-type BRAF and results in loss of its catalytic activity in cells 4,12 . However, full-length BRAF(V600E/R509H) expressed in 293H cells retained its ability to fully activate ERK signalling and remained sensitive to vemurafenib ( Fig. 2d ). Moreover, BRAF(V600E/R509H) fully activated ERK signalling when expressed in either BRAF-null or ARAF/CRAF-null mouse embryonic fibroblasts ( Supplementary Fig. 12a, b) . These results show that, in contrast to wild-type BRAF, BRAF(V600E) can signal as a monomer and that active RAS and dimerization are not necessary for its activation.
Our model implies that, in tumours with BRAF(V600E), elevation of RAS-GTP or alterations that cause increased RAF dimerization in the absence of RAS activation will confer resistance to RAF inhibitors 4, 13 . To test whether resistance mediated by p61BRAF(V600E) was the result of elevated dimer formation, we introduced the R509H dimerizationdeficient mutation into p61BRAF(V600E). In 293H cells expressing p61BRAF(V600E), phosphorylation of ERK was elevated and was insensitive to vemurafenib ( Fig. 2e ). ERK activity was also elevated in cells expressing p61BRAF(V600E/R509H), but to a slightly lesser degree. p61BRAF(V600E/R509H) showed impaired dimerization, confirming that the R509H mutation located within the dimerization interface disrupts the formation of p61RAF(V600E) dimers ( Fig. 2c and Supplementary Fig. 13 ). Finally, this monomeric p61BRAF(V600E/ R509H) was sensitive to RAF inhibitors; in cells ectopically expressing this mutant, ERK signalling was inhibited by vemurafenib ( Fig. 2e) . Thus, the R509H mutation restores sensitivity to the RAF inhibitor by impairing dimerization of p61BRAF(V600E).
To determine whether BRAF variants can account for clinical resistance to RAF inhibitors, we analysed tumours from nineteen melanoma patients with acquired resistance to vemurafenib. PCR analysis of cDNA from pre-treatment samples showed a single band of the expected size (2.3 kb), which was sequenced and confirmed to include both BRAF(V600E) and wild-type BRAF transcripts (Fig. 3a, b and data not shown). We identified two PCR products in six of the post-treatment progression samples, including three with matching pre-treatment samples. The shorter PCR products encoded BRAF(V600E) transcripts lacking exons 4-10 (patient 1), exons 4-8, (patient 11, identical to the variant identified in the resistant cell lines), exons 2-8 (patient 12), or exons 2-10 (patients 5, 6 and 19) ( Fig. 3a-c 
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progression samples and were found to be mutually exclusive with BRAF splicing variants. BRAF splicing variants were not detected in two samples derived from patients with intrinsic resistance (patient 20 shown) or in 27 additional melanomas resected from vemurafenib-naive patients ( Fig. 3a , Supplementary Table 1 and data not shown). Thus, we did not detect significant levels of BRAF splicing variants in melanoma cell lines and tumours that have not been exposed to RAF inhibitors. However, the assay used cannot exclude the possibility that such variants may be expressed in small amounts before drug selection and subsequently selected under conditions of continuous treatment with the drug. In tumours from patients that have been analysed, resistance to vemurafenib is frequently associated with inability of the drug to inhibit ERK signalling 14 . Our model indicates that this can be due to increased RAF dimer formation in the cell 4 . This can happen in at least two ways: increasing RAS-GTP levels and induction of RAS-independent dimerization ( Supplementary Fig. 1a, b) . NRAS mutation has recently been reported in resistant tumours 15 . Other mechanisms of resistance to RAF inhibitors in model systems and in patients have also been reported, including activation of receptor tyrosine kinases, COT overexpression and MEK1 mutation [15] [16] [17] [18] . We now report a lesion in patient tumours that results in RAF inhibitor resistance by inducing increased, RAS-independent dimerization.
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Expression of BRAF(V600E) splicing variants is the first resistance mechanism identified that involves a structural change in BRAF. In each case, the alternative splicing forms identified in the cell lines and patients were in-frame and confined to the mutant BRAF allele. This suggests that generation of the splicing variants is probably due to a mutation or epigenetic change that affects BRAF splicing and not to a loss of global splicing fidelity 19 . The identification of BRAF variants lacking the RAS-binding domain in six of nineteen patients with acquired resistance indicates that this mechanism is clinically important. Acquired resistance mediated by BRAF(V600E) splicing variants is due to insensitivity of the enzyme to RAF inhibitors. These tumours should retain sensitivity to inhibitors of downstream components of the pathway such as MEK, which was indeed the case (Supplementary Fig. 3 ). Therefore, MEK inhibitors used in combination with vemurafenib could delay or prevent resistance by this mechanism.
METHODS SUMMARY
Vemurafenib 20 (PLX4032) was obtained from Plexxikon. PD0325901 was synthesized in the MSKCC Organic Synthesis Core Facility by O. Ouerfelli. Flag-tagged BRAF constructs have been described previously 4 . All other plasmids were created using standard cloning methods, with pcDNA3.1 (Invitrogen) as a vector. Mutations were introduced using a site-directed mutagenesis kit (Stratagene). The C1-5 vemurafenib-resistant cells were generated by continuous exposure of parental SKMEL-239 cells to 2 mM of drug until the emergence of resistant colonies. Single-cell cloning was then performed before biological characterization.
For cDNA preparation, a Superscript III First-Strand Synthesis kit (Invitrogen) was used. Sanger sequencing of the products was performed by Genewiz. For qPCR analysis, cDNA synthesis was carried out with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qPCR was performed with a iQ SYBR Green RT-PCR Super Mix (Bio-Rad) and a C1000 Thermal Cycler (Bio-Rad). The comparative C t method was used to quantify transcripts and delta C t was measured in triplicate. Sequences of all primers used are available upon request.
Melanoma tumour specimens from patients treated with vemurafenib were collected following IRB-approved protocols and were flash-frozen immediately after resection or biopsy. To determine tumour content, 5-mm sections were cut, stained with haematoxylin and eosin, and scored by a pathologist. If the specimen had .70% tumour content (excluding necrosis), the remainder of the frozen tumour was homogenized using a Bullet Blender (Next Advance) with 0.9-2 mm stainless steel beads for 5 min at a speed setting of 10. RNA was then extracted from the tumour homogenate using an RNeasy Mini kit (Qiagen) and quantified.
